WuXi Biologics H1 net profit up on margin expansion

WuXi Biologics (Cayman)

25/08/2026 13:41

Overview
China biologics CDMO's H1 revenue grew 18% yr/yr, net profit attributable up 4%
Gross profit margin expanded to 46.2% from 42.7%
Growth driven by expanded project portfolio and more late-phase, commercial manufacturing projects

Outlook
Company did not provide specific financial guidance for the current or future periods

Result Drivers
EXPANDED PROJECT PORTFOLIO - Co said revenue growth was driven by the addition of 169 new integrated projects, bringing the total to 1,064 as of June 30, 2026
LATE-PHASE AND COMMERCIAL PROJECTS - Growth in late-phase and commercial manufacturing projects contributed to higher revenue and gross profit margin
GROSS MARGIN EXPANSION - Gross profit margin rose to 46.2%, which the co attributed to increased project scale and higher-value services

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
RMB 11.79 bln
 
H1 Net Income Attributable
 
RMB 2.44 bln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for WuXi Biologics (Cayman) Inc. is HK$46.90, about 10.2% below its August 25 closing price of HK$52.20
The stock recently traded at 27 times the next 12-month earnings vs. a P/E of 19 three months ago

Reuters Recommended Reads
Aug 24 - Chinese drugmaker Wuxi XDC's first-half revenue rises on project expansion, acquisition
Aug 24 - China's RemeGen H1 revenue soars on drug sales, AbbVie deal
Aug 24 - China's Asymchem H1 revenue rises on strength in emerging businesses

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)